<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120003</url>
  </required_header>
  <id_info>
    <org_study_id>050321</org_study_id>
    <nct_id>NCT00120003</nct_id>
  </id_info>
  <brief_title>Scandinavian Candesartan Acute Stroke Trial (SCAST)</brief_title>
  <official_title>Scandinavian Candesartan Acute Stroke Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern-Eastern Norway Health Authorities RHF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess whether the blood pressure lowering agent candesartan&#xD;
      (an angiotensin receptor type 1 blocker) is effective when given to patients with acute&#xD;
      stroke and elevated blood pressure.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      AT1 receptor blockade with candesartan in acute stroke will:&#xD;
&#xD;
        1. reduce the risk of death or major disability at 6 months by a 6% absolute risk&#xD;
           reduction, relative to placebo.&#xD;
&#xD;
        2. reduce the risk of the combined event of &quot;vascular&quot; death, myocardial infarction, or&#xD;
           stroke during the first 6 months by a 25% relative risk reduction, relative to placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has long been a controversy whether elevated blood pressure should be lowered in the acute&#xD;
      phase of stroke. Current clinical practice is generally to accept high blood pressure in the&#xD;
      acute phase of stroke, to avoid reduction of cerebral blood perfusion. This practice has a&#xD;
      well-founded theoretical basis, but is not supported by evidence from clinical trials. The&#xD;
      newly published study ACCESS (Stroke 2003;34:1699) showed a clear beneficial effect of the&#xD;
      angiotensin receptor blocker candesartan in the acute phase of stroke, but the trial was&#xD;
      seriously underpowered.&#xD;
&#xD;
      The Scandinavian Candesartan Acute Stroke Trial (SCAST) is designed to provide reliable data&#xD;
      on the effects of candesartan in a wide variety of patients with acute stroke (target&#xD;
      recruitment 2,500). Patients presenting with acute stroke (&lt;30 hours) and systolic blood&#xD;
      pressure ≥140 mm Hg will be randomly assigned to candesartan 4 to 16 mg once daily or&#xD;
      matching placebo for 7 days, followed by candesartan treatment for 6 months for patients who&#xD;
      are hypertensive at the end of the treatment period (at clinician's discretion). Follow-up&#xD;
      will be performed double-blind at 30 days, 3 months and 6 months.&#xD;
&#xD;
      The trial is co-ordinated from Ullevaal University Hospital in Oslo, Norway. Over 100 centres&#xD;
      from Norway, Sweden, Denmark and Belgium have agreed to participate. Financial contributors:&#xD;
      The Eastern Norway Regional Health Authority, AstraZeneca, and Ullevaal University Hospital&#xD;
      (Oslo). AstraZeneca will supply drugs and placebo for the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or major disability (defined by the modified Rankin scale) at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The composite event &quot;vascular&quot; death, myocardial infarction, or stroke during the first 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scandinavian Stroke Scale score at 7 days</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index score at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol score at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State score at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (all-cause death and &quot;vascular&quot; death)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent stroke (ischaemic, haemorrhagic, or unspecified)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination of the above events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic hypotension</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal failure</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Candesartan Cilexetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan Cilexetil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil</intervention_name>
    <description>4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7</description>
    <arm_group_label>Candesartan Cilexetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical stroke syndrome with limb paresis, not likely to represent a transient&#xD;
             ischaemic attack or non-stroke pathology (e.g. cerebral tumour)&#xD;
&#xD;
          -  Systolic blood pressure ≥ 140 mm Hg&#xD;
&#xD;
          -  Trial treatment possible within 30 hrs of symptom onset. If time of onset is not&#xD;
             known, use the time when the patient was last known to be well.&#xD;
&#xD;
          -  Consent (subsidiary, assent from legal acceptable representative, or waiver of&#xD;
             consent)&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Markedly reduced consciousness (i.e. Scandinavian Stroke Scale consciousness score ≤&#xD;
             2)&#xD;
&#xD;
          -  Patient already receiving AT1 receptor blocker&#xD;
&#xD;
          -  Contraindication to treatment with AT1 receptor blocker, e.g.:&#xD;
&#xD;
               -  known renal failure (women: creatinine ≥ 150 µmol/L; men: ≥ 180 µmol/L)&#xD;
&#xD;
               -  previously diagnosed bilateral renal artery stenosis&#xD;
&#xD;
               -  previously diagnosed high-grade aortic stenosis&#xD;
&#xD;
               -  previously diagnosed seriously impaired liver function and/or cholestasis&#xD;
&#xD;
               -  known intolerance to candesartan or other tablet ingredients&#xD;
&#xD;
          -  Clear indication, in the clinician's view, for start of treatment with AT1 receptor&#xD;
             blocker during the treatment period (e.g. chronic heart failure grade III-IV, in the&#xD;
             presence of intolerance to ACE inhibitors)&#xD;
&#xD;
          -  Clear indication, in the clinician's view, for antihypertensive therapy during the&#xD;
             acute phase of stroke (i.e. concurrent hypertensive encephalopathy or aortic&#xD;
             dissection, or other situations)&#xD;
&#xD;
          -  Other serious or life-threatening disease before the stroke:&#xD;
&#xD;
          -  Patient severely mentally or physically disabled (e.g. Mini Mental Status score &lt; 20,&#xD;
             or modified Rankin Scale score ≥ 4)&#xD;
&#xD;
          -  Life expectancy &lt; 12 months&#xD;
&#xD;
          -  Patient unavailable for follow-up (e.g. no fixed address)&#xD;
&#xD;
          -  Pregnant or breast-feeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eivind Berge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Morten Sandset, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Povel Paus, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ullevaal University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://www.scast.no</url>
    <description>Click here for more information about this trial</description>
  </link>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>July 6, 2005</study_first_submitted>
  <study_first_submitted_qc>July 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2005</study_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director of Research Andreas Moan</name_title>
    <organization>Ullevaal University Hospital</organization>
  </responsible_party>
  <keyword>Acute stroke</keyword>
  <keyword>Elevated blood pressure</keyword>
  <keyword>Blood pressure lowering treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

